Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ESRRA | P11474 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854690 | 1.00 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL5854219 | 1.00 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL5854790 | 1.00 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL7087553 | 1.00 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL5856153 | 1.00 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL7130553 | 0.99 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL7121851 | 0.99 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL7117919 | 0.99 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL7119240 | 0.99 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR | |
| SCHEMBL7124146 | 0.99 | ESR1 (0.47) | ESR1ARNR1I2NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555571-B2 | Hormone inhibitor; sexual disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | claimed |
| EP-1240156-A4 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-04-16 | — | — | EP | claimed |
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-01-16 | — | — | US | claimed |
| EP-1240156-A1 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | claimed |
| WO-2001042237-A1 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-06-14 | — | — | WO | claimed |
| US-6555571-B2 | Hormone inhibitor; sexual disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1240156-A4 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-1240156-A1 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042237-A1 | 3-METHYL-CHROMANE OR THIOCHROMANE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | ESR2, GPER1, NR5A1 | ESR1 5/4885AR 26/4885NR1I2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.